Palbociclib (monohydrochloride)

CDK

Reference compound

Cell Cycle/DNA Damage

Cancer-Kinase/protease

Cancer

https://www.medchemexpress.com/palbociclib-monohydrochloride.html

99.98

DMSO : 4.63 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : 7.14 mg/mL (ultrasonic;warming;heat to 60°C)

O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5.Cl

483.99

[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. |[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. |[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. |[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296. bioRxiv. 2023 Mar 15.|Cancer Res. 2022 Apr 11;canres.3565.2021.|Cell Rep. 2022 Mar 1;38(9):110448.|Cell Rep. 2023 Mar 30;42(4):112314.|Ecotoxicol Environ Saf. 2020 Dec 1;205:111146.|Eur J Cancer. 2018 Oct;102:10-22.|J Pathol. 2023 Feb 24.|J Transl Med. 2023 Feb 10;21(1):110.|Mol Cancer Res. 2018 Mar;16(3):361-377. |Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. |Mol Cell. 2023 Nov 16;83(22):4062-4077.e5.|Mol Oncol. 2017 Aug;11(8):1035-1049.|Nature. 2017 Jun 15;546(7658):426-430.|Sci Data. 2024 Sep 19.|University College Dublin. School of Biology and Environmental Science.|Acta Biomater. 2022 Aug 1;S1742-7061(22)00455-X.|Adv Sci (Weinh). 2024 Aug 13:e2400666.|Am J Transl Res. 2019 Sep 15;11(9):6055-6065.|Biochem Biophys Res Commun. 2023 Apr 2;650:96-102.|Biochem Pharmacol. 2017 Jan 15;124:29-42.|Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363.|bioRxiv. 2023 Nov 23.|bioRxiv. 2023 Sep 18.|bioRxiv. 2024 Dec 5:2024.12.05.627000.|bioRxiv. 2024 July 05.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2024 Oct 9:2024.10.08.617155.|Br J Cancer. 2021 Jan;124(1):191-206.|Br J Cancer. 2022 Jan 14.|Breast Cancer Res. 2024 Jun 7;26(1):95.|Cancer Cell. 2017 Apr 10;31(4):576-590.e8. |Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2.|Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.|Cancer Discov. 2024 Sep 13:OF1-OF20.|Cancer Lett. 2024 May 28:216996.|Cancer Res. 2019 Oct 15;79(20):5245-5259.|Cancer Res. 2021 Jan 1;81(1):187-198.|Cancer Res. 2023 Apr 18;CAN-22-3484.|Cancer Res. 2023 Oct 6.|Cancers (Basel). 2021, 13(7), 1494.|Cancers (Basel). 2023 Mar 22;15(6):1908.|Cancers (Basel). 2024 Aug 7;16(16):2785.|Cancers. 2020 Jun 16;12(6):1596.|Cell Biochem Biophys. 2024 Sep 24.|Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.|Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. |Cell Death Differ. 2020 Jun;27(6):1981-1997.|Cell Death Differ. 2022 Jan 20.|Cell Death Dis. 2020 Apr 6;11(4):219. |Cell Death Dis. 2020 Sep 15;11(9):760.|Cell Death Dis. 2022 Apr 2;13(4):295.|Cell Death Discov. 2024 Oct 26;10(1):453.|Cell Mol Gastroenterol Hepatol. 2022 Jul 14;S2352-345X(22)00163-1.|Cell Prolif. 2022 Sep 20;e13337.|Cell Rep. 2022 Aug 16;40(7):111194.|Cell Rep. 2022 Nov 15;111716.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell Syst. 2019 Jul 24;9(1):35-48.e5. |Cell Rep. 2020 Apr 14;31(2):107514.|Cells. 2023 Dec 30, 13(1), 81.|Clin Cancer Res. 2021 Apr 1;27(7):1855-1863.|Clin Cancer Res. 2024 Jul 25.|Department of Biochemistry. 2020 Oct.|Dev Cell. 2023 Sep 9;S1534-5807(23)00443-4.|Development. 2023 Apr 5;dev.200903.|EBioMedicine. 2019 May;43:171-179. |EBioMedicine. 2019 May;43:225-237. |EBioMedicine. 2024 Jul.|EMBO J. 2021 Apr 15;e99692.|EMBO J. 2024 Aug 19.|EMBO J. 2024 Sep 26.|EMBO Rep. 2022 Apr 11;e53932.|Endocrinology. 2023 Sep 13;bqad135.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Front Cell Dev Biol. 2020 Aug 31;8:843.|Front Oncol. 2022 Apr 8;12:819003.|Future Med Chem. 2018 Dec 17. |Harvard Medical School LINCS LIBRARY|Inflamm Res. 2023 May 11.|Int J Biol Sci. 2019 Jan 1;15(3):522-532. |Int J Biol Sci. 2021; 17(3): 728-741.|Int J Biol Sci. 2024 Sep 16;20(12):4978-4998.|Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. |Int J Mol Sci. 2021, 22(7), 3367.|Int J Mol Sci. 2023 Mar 12.|iScience. 6 September 2022, 105081.|J Biol Chem. 2023 May 3;104786.|J Biol Chem. 2023 Oct 17.|J Bone Oncol. October 2021, 100391.|J Cell Mol Med. 2021 Mar;25(6):3124-3135.|J Exp Clin Cancer Res. 2018 Sep 20;37(1):233.|J Med Chem. 2021 Jul 21.|J Med Chem. 2021 Oct 21.|J Oncol. 27 Sept 2022.|J Transl Med. 2019 Aug 20;17(1):276.|JCI Insight. 2021 Apr 8;6(7):139497.|JHEP Rep. 2024 Oct 5;7(1):101230.|Leuk Res. September 2022, 106920.|Life Sciences. 2023 Apr 1, 121652.|Mar Drugs. 2020 Sep 27;18(10):494.|MedComm. 10 June 2022.|Mol Cell. 2017 Oct 19;68(2):336-349.e6.|Mol Cell. 2023 Oct 5;83(19):3558-3573.e7.|Mol Oncol. 2023 Sep 13.|Mol Ther-Nucl Acids. 2023 Mar.|Molecules. 2023 May 27, 28(11), 4380.|Nat Commun. 2018 Oct 9;9(1):4180. |Nat Commun. 2020 Aug 13;11(1):4053.|Nat Commun. 2021 Jul 22;12(1):4457.|Nat Commun. 2021 Nov 16;12(1):6607.|Nat Commun. 2023 Jul 14;14(1):4221.|Nat Commun. 2024 Feb 16;15(1):1442.|Nat Commun. 2019 Nov 7;10(1):5076. |Nat Methods. 2022 Mar;19(3):331-340.|Nature Cancer. 2021 Jan;2(1):34-48.|Nature. 2017 Aug 24;548(7668):471-475. |Nature. 2020 Jul;583(7817):620-624.|Neoplasia. 2018 Mar 28;20(5):478-488. |Neoplasia. 2024 Aug 14:57:101039.|NPJ Precis Oncol. 2021 Mar 19;5(1):20.|Oncogene. 2022 Jun 9.|Patent. US11761044.|Patent. US20200108066A1|Patent. US20230149350A1.|Patent. US20240307414A1.|Phytomedicine. 2024 May 28:131:155775.|PLoS One. 2024 Aug 8;19(8):e0306545.|PLoS One. 2024 Jul 11;19(7):e0305612.|PRACTICAL ONCOLOGY JOURNAL. 2018, 32(3): 193-197.|Practical Oncology Journal. 2018,32(03):193-197.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2023 Nov 30.|Research Square Preprint. 2024 Nov 06.|Sci Rep. 2021 Mar 8;11(1):5374.|Sci Rep. 2023 Jan 31;13(1):1711.|Sci Rep. 2024 May 8;14(1):10582.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2022 Nov 21.|Technischen Universität Dresden . 11 June 2021.|Technischen Universität München. Fakultät für Medizin.|Texas Southern University. 2024 July 02.|University of Coruña. Facultade de Ciencias da Saúde. 2022 Oct.|University of Coruña. Facultade de Ciencias. 2022 Jan.|University of Dundee. 2023 Jan.|University of Texas. UTHealth Graduate School of Biomedical Sciences. 2021 Sep.|World J Surg Surgical Res. 2023 Jun 28.|Aging Cell. 2022 Mar 9;e13580.|bioRxiv. 2023 Mar 30.|bioRxiv. 2023 Sep 16.|Cancer Res. 2023 Jun 29;CAN-23-0705.|Cell Rep. 2019 Mar 5;26(10):2667-2680.e7.|EMBO J. 2022 Feb 14;e109760.|J Virol. 2023 May 23;e0037023.|Laurentian University. Chemical Sciences. 2021 Oct.|Mol Cancer. 2022 Aug 30;21(1):171.|Mol Cancer. 2024 Jun 3;23(1):118.|Nat Commun. 2021 Aug 25;12(1):5112.|Nat Commun. 2022 Aug 10;13(1):4689.|Nature. 2020 Dec;588(7836):169-173.|NPJ Breast Cancer. 2021 Jan 4;7(1):2.|Syddansk Universitet. 2023 May 22.|bioRxiv. 2024 Nov 6:2024.11.04.621884.,[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. |[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. |[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. |[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296. bioRxiv. 2023 Mar 15.|Cancer Res. 2022 Apr 11;canres.3565.2021.|Cell Rep. 2022 Mar 1;38(9):110448.|Cell Rep. 2023 Mar 30;42(4):112314.|Ecotoxicol Environ Saf. 2020 Dec 1;205:111146.|Eur J Cancer. 2018 Oct;102:10-22.|J Pathol. 2023 Feb 24.|J Transl Med. 2023 Feb 10;21(1):110.|Mol Cancer Res. 2018 Mar;16(3):361-377. |Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. |Mol Cell. 2023 Nov 16;83(22):4062-4077.e5.|Mol Oncol. 2017 Aug;11(8):1035-1049.|Nature. 2017 Jun 15;546(7658):426-430.|Sci Data. 2024 Sep 19.|University College Dublin. School of Biology and Environmental Science.|Acta Biomater. 2022 Aug 1;S1742-7061(22)00455-X.|Adv Sci (Weinh). 2024 Aug 13:e2400666.|Am J Transl Res. 2019 Sep 15;11(9):6055-6065.|Biochem Biophys Res Commun. 2023 Apr 2;650:96-102.|Biochem Pharmacol. 2017 Jan 15;124:29-42.|Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363.|bioRxiv. 2023 Nov 23.|bioRxiv. 2023 Sep 18.|bioRxiv. 2024 Dec 5:2024.12.05.627000.|bioRxiv. 2024 July 05.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2024 Oct 9:2024.10.08.617155.|Br J Cancer. 2021 Jan;124(1):191-206.|Br J Cancer. 2022 Jan 14.|Breast Cancer Res. 2024 Jun 7;26(1):95.|Cancer Cell. 2017 Apr 10;31(4):576-590.e8. |Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2.|Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.|Cancer Discov. 2024 Sep 13:OF1-OF20.|Cancer Lett. 2024 May 28:216996.|Cancer Res. 2019 Oct 15;79(20):5245-5259.|Cancer Res. 2021 Jan 1;81(1):187-198.|Cancer Res. 2023 Apr 18;CAN-22-3484.|Cancer Res. 2023 Oct 6.|Cancers (Basel). 2021, 13(7), 1494.|Cancers (Basel). 2023 Mar 22;15(6):1908.|Cancers (Basel). 2024 Aug 7;16(16):2785.|Cancers. 2020 Jun 16;12(6):1596.|Cell Biochem Biophys. 2024 Sep 24.|Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.|Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. |Cell Death Differ. 2020 Jun;27(6):1981-1997.|Cell Death Differ. 2022 Jan 20.|Cell Death Dis. 2020 Apr 6;11(4):219. |Cell Death Dis. 2020 Sep 15;11(9):760.|Cell Death Dis. 2022 Apr 2;13(4):295.|Cell Death Discov. 2024 Oct 26;10(1):453.|Cell Mol Gastroenterol Hepatol. 2022 Jul 14;S2352-345X(22)00163-1.|Cell Prolif. 2022 Sep 20;e13337.|Cell Rep. 2022 Aug 16;40(7):111194.|Cell Rep. 2022 Nov 15;111716.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell Syst. 2019 Jul 24;9(1):35-48.e5. |Cell Rep. 2020 Apr 14;31(2):107514.|Cells. 2023 Dec 30, 13(1), 81.|Clin Cancer Res. 2021 Apr 1;27(7):1855-1863.|Clin Cancer Res. 2024 Jul 25.|Department of Biochemistry. 2020 Oct.|Dev Cell. 2023 Sep 9;S1534-5807(23)00443-4.|Development. 2023 Apr 5;dev.200903.|EBioMedicine. 2019 May;43:171-179. |EBioMedicine. 2019 May;43:225-237. |EBioMedicine. 2024 Jul.|EMBO J. 2021 Apr 15;e99692.|EMBO J. 2024 Aug 19.|EMBO J. 2024 Sep 26.|EMBO Rep. 2022 Apr 11;e53932.|Endocrinology. 2023 Sep 13;bqad135.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Front Cell Dev Biol. 2020 Aug 31;8:843.|Front Oncol. 2022 Apr 8;12:819003.|Future Med Chem. 2018 Dec 17. |Harvard Medical School LINCS LIBRARY|Inflamm Res. 2023 May 11.|Int J Biol Sci. 2019 Jan 1;15(3):522-532. |Int J Biol Sci. 2021; 17(3): 728-741.|Int J Biol Sci. 2024 Sep 16;20(12):4978-4998.|Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. |Int J Mol Sci. 2021, 22(7), 3367.|Int J Mol Sci. 2023 Mar 12.|iScience. 6 September 2022, 105081.|J Biol Chem. 2023 May 3;104786.|J Biol Chem. 2023 Oct 17.|J Bone Oncol. October 2021, 100391.|J Cell Mol Med. 2021 Mar;25(6):3124-3135.|J Exp Clin Cancer Res. 2018 Sep 20;37(1):233.|J Med Chem. 2021 Jul 21.|J Med Chem. 2021 Oct 21.|J Oncol. 27 Sept 2022.|J Transl Med. 2019 Aug 20;17(1):276.|JCI Insight. 2021 Apr 8;6(7):139497.|JHEP Rep. 2024 Oct 5;7(1):101230.|Leuk Res. September 2022, 106920.|Life Sciences. 2023 Apr 1, 121652.|Mar Drugs. 2020 Sep 27;18(10):494.|MedComm. 10 June 2022.|Mol Cell. 2017 Oct 19;68(2):336-349.e6.|Mol Cell. 2023 Oct 5;83(19):3558-3573.e7.|Mol Oncol. 2023 Sep 13.|Mol Ther-Nucl Acids. 2023 Mar.|Molecules. 2023 May 27, 28(11), 4380.|Nat Commun. 2018 Oct 9;9(1):4180. |Nat Commun. 2020 Aug 13;11(1):4053.|Nat Commun. 2021 Jul 22;12(1):4457.|Nat Commun. 2021 Nov 16;12(1):6607.|Nat Commun. 2023 Jul 14;14(1):4221.|Nat Commun. 2024 Feb 16;15(1):1442.|Nat Commun. 2019 Nov 7;10(1):5076. |Nat Methods. 2022 Mar;19(3):331-340.|Nature Cancer. 2021 Jan;2(1):34-48.|Nature. 2017 Aug 24;548(7668):471-475. |Nature. 2020 Jul;583(7817):620-624.|Neoplasia. 2018 Mar 28;20(5):478-488. |Neoplasia. 2024 Aug 14:57:101039.|NPJ Precis Oncol. 2021 Mar 19;5(1):20.|Oncogene. 2022 Jun 9.|Patent. US11761044.|Patent. US20200108066A1|Patent. US20230149350A1.|Patent. US20240307414A1.|Phytomedicine. 2024 May 28:131:155775.|PLoS One. 2024 Aug 8;19(8):e0306545.|PLoS One. 2024 Jul 11;19(7):e0305612.|PRACTICAL ONCOLOGY JOURNAL. 2018, 32(3): 193-197.|Practical Oncology Journal. 2018,32(03):193-197.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2023 Nov 30.|Research Square Preprint. 2024 Nov 06.|Sci Rep. 2021 Mar 8;11(1):5374.|Sci Rep. 2023 Jan 31;13(1):1711.|Sci Rep. 2024 May 8;14(1):10582.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2022 Nov 21.|Technischen Universit��t Dresden . 11 June 2021.|Technischen Universität München. Fakultät für Medizin.|Texas Southern University. 2024 July 02.|University of Coruña. Facultade de Ciencias da Saúde. 2022 Oct.|University of Coruña. Facultade de Ciencias. 2022 Jan.|University of Dundee. 2023 Jan.|University of Texas. UTHealth Graduate School of Biomedical Sciences. 2021 Sep.|World J Surg Surgical Res. 2023 Jun 28.|Aging Cell. 2022 Mar 9;e13580.|bioRxiv. 2023 Mar 30.|bioRxiv. 2023 Sep 16.|Cancer Res. 2023 Jun 29;CAN-23-0705.|Cell Rep. 2019 Mar 5;26(10):2667-2680.e7.|EMBO J. 2022 Feb 14;e109760.|J Virol. 2023 May 23;e0037023.|Laurentian University. Chemical Sciences. 2021 Oct.|Mol Cancer. 2022 Aug 30;21(1):171.|Mol Cancer. 2024 Jun 3;23(1):118.|Nat Commun. 2021 Aug 25;12(1):5112.|Nat Commun. 2022 Aug 10;13(1):4689.|Nature. 2020 Dec;588(7836):169-173.|NPJ Breast Cancer. 2021 Jan 4;7(1):2.|Syddansk Universitet. 2023 May 22.|bioRxiv. 2024 Nov 6:2024.11.04.621884.

Room Temperature

4°C (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-50767A/Palbociclib-monohydrochloride-DataSheet-MedChemExpress.pdf

http://file.medchemexpress.com/batch_PDF/HY-50767A/Palbociclib-monohydrochloride-SDS-MedChemExpress.pdf

Launched

827022-32-2